This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABT-652

AbbVie Inc.

Drug Names(s): ABT-652

Description: ABT-652 targets the histamine 3 receptor (H3).

ABT-652 News

Pink Sheet Consumer Health Weekly Trademark Review Nov. 21, 2017

Pink Sheet Patients Aren’t Adhering To Sovaldi As Much As They Should – CVS Study

Scrip FDA bestows 'breakthrough' on AbbVie hep C combo, Scioderm 'fragile skin' therapy

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug